{
  "event": {
    "ticker": "CAPR",
    "company": "Capricor Therapeutics, Inc.",
    "drug": "deramiocel",
    "application_type": "BLA",
    "indication": "Duchenne muscular dystrophy (refined proposed indication focused on upper limb function; originally filed for DMD cardiomyopathy)",
    "pdufa_date": "2026-11-22"
  },
  "display": {
    "company": "Capricor",
    "drug": "deramiocel",
    "indication_en": "Duchenne muscular dystrophy",
    "indication_zh": "杜氏肌营养不良"
  },
  "probability_approval": 0.2,
  "confidence": "low",
  "base_rate_used": 0.76,
  "key_factors": [
    {
      "factor": "FDA reviewers say the pivotal trial failed, for upper limb as well as heart",
      "direction": "-",
      "step": "large",
      "evidence": "In its briefing document for the 29 July 2026 advisory committee, FDA analysed HOPE-3 under the original analysis plan: the primary endpoint (PUL 2.0 total score) differed by 0.66 points (95% CI -0.45 to 1.77; p=0.24) in a trial powered to detect 1.5 points, and the key secondary endpoint (LVEF) by -0.041 percentage points (p=0.97). The reviewers concluded that the data do \"not provide substantial evidence of effectiveness for deramiocel in DMD\", that they were \"unable to identify a subpopulation that may potentially derive benefit\", and that benefit-risk \"appears unfavorable\". The conclusion covers upper limb function, the indication now under review.",
      "source": "FDA Briefing Document, BLA 125842, advisory committee meeting of 2026-07-29, sections 3.2.4.2-3.2.4.4 and 4: https://www.fda.gov/media/193839/download; FDA presentation, slides 54 and 61: https://www.fda.gov/media/193912/download"
    },
    {
      "factor": "The company's positive result depends on an analysis plan rewritten after the trial",
      "direction": "-",
      "step": "large",
      "evidence": "Capricor reports a significant primary result (4.55 percentage points, p=0.029; published in The Lancet in July 2026). FDA says the plan behind it, version 3.0 dated 24 November 2025, more than five months after the blinded period ended on 18 June 2025 and one day before the data were unblinded on 25 November 2025, \"was not submitted to FDA for review\" before the filing, and it treats the resulting analyses as post hoc and exploratory. In FDA's re-analysis, version 3.0 as written gives 4.16% (p=0.045); with the original handling of two placebo patients' data it falls to 2.53% (p=0.21). Version 2.0, the last plan sent to FDA (26 September 2025), gives 3.74% (p=0.08) or 2.38% (p=0.26). On 29 July 2026 Capricor itself corrected its LVEF result to p=0.09 (a difference of 1.8 percentage points) from p=0.04 (2.4 percentage points).",
      "source": "FDA Briefing Document, sections 1.3 and 3.2.4.2-3.2.4.3, Tables 3, 7 and 12: https://www.fda.gov/media/193839/download; Capricor 8-K, 2026-07-29: https://www.sec.gov/Archives/edgar/data/1133869/000110465926087891/capr-20260729x8k.htm; Capricor 8-K exhibit 99.1, 2026-08-13: https://www.sec.gov/Archives/edgar/data/1133869/000110465926095908/capr-20260813xex99d1.htm"
    },
    {
      "factor": "A second review cycle after an efficacy rejection, with no independent confirmation",
      "direction": "-",
      "step": "medium",
      "evidence": "FDA's complete response letter of 9 July 2025 said the application \"does not meet the statutory requirement for substantial evidence of effectiveness\". Its request for a controlled study with cardiac outcomes as the primary objective applied if Capricor sought the cardiomyopathy indication; for a general DMD indication FDA had recommended in August 2024 that the application include HOPE-3, and in August 2025 it declined to let Capricor switch HOPE-3's primary endpoint to LVEF. HOPE-3 is therefore the relevant trial for an upper-limb claim, but it stands alone: the earlier HOPE-2 trial (20 patients, stopped early) missed its primary endpoint (2.98 points, p=0.13), and FDA writes that the proposed mechanism is not specific enough to be \"biologically plausible as a disease-modifying therapy\". The first resubmission (29 December 2025) was ruled incomplete on 13 January 2026. The 76% base rate describes first-time applications.",
      "source": "FDA Complete Response Letter, BL 125842/0, 2025-07-09: https://download.open.fda.gov/crl/CRL_BLA125842_20250709.pdf; FDA Briefing Document, Table 3 and section 3.2.4.6: https://www.fda.gov/media/193839/download; FDA presentation, slide 60: https://www.fda.gov/media/193912/download"
    },
    {
      "factor": "The advisory committee voted 3-9 against on the heart indication; upper limb was not put to a vote",
      "direction": "-",
      "step": "small",
      "evidence": "On 29 July 2026 FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 3 yes, 9 no, 0 abstain on whether there is substantial evidence that deramiocel is effective for cardiomyopathy in DMD. Upper limb function was a discussion topic without a vote, so the indication now under review has no committee endorsement. Press accounts say members who voted no cited results that were sensitive to the handling of missing data, mainly for LVEF and to a lesser extent for the upper-limb endpoint; one statistician called the results very fragile, and another rated the upper-limb data somewhat better but said he was still not persuaded the product works. Members who voted yes pointed to the upper-limb data. Capricor describes the upper-limb discussion as directionally supportive; that is the company's wording.",
      "source": "Capricor 8-K, 2026-07-30: https://www.sec.gov/Archives/edgar/data/1133869/000110465926088667/capr-20260729x8k.htm; FDA voting question, 2026-07-29: https://www.fda.gov/media/193857/download; FDA discussion topics, 2026-07-29: https://www.fda.gov/media/193913/download; BioSpace, 2026-07-29: https://www.biospace.com/fda/fda-advisers-vote-against-approval-of-capricors-dmd-therapy-in-chaotic-adcomm-meeting; NeurologyLive, 2026-07-29: https://www.neurologylive.com/view/fda-advisory-committee-votes-against-deramiocel-dmd-cardiomyopathy; BioPharma Dive, 2026-07-29: https://www.biopharmadive.com/news/capricor-fda-vote-deramiocel-duchenne-cardiomyopathy/826465/"
    },
    {
      "factor": "The amendment adds only uncontrolled data",
      "direction": "-",
      "step": "small",
      "evidence": "The August amendment adds 24-month open-label extension data and further analyses, not a new randomized comparison. FDA had asked for long-term clinical data on 14 May 2026. Capricor says 82 of the 106 randomized patients reached month 24 (40 originally on deramiocel, 42 on placebo); 101 had completed the blinded year. As reported from a World Muscle Society congress poster on 30 September 2026, patients switched from placebo declined 2.05 PUL points in the blinded year and 0.49 in the open-label year; patients on deramiocel throughout declined 0.95 and then 0.89. FDA has written that PUL scores \"may be susceptible to bias\" under open-label conditions, and told the committee that post hoc analyses of the earlier open-label study cannot provide substantial evidence of effectiveness.",
      "source": "Capricor 8-K exhibit 99.1, 2026-08-24: https://www.sec.gov/Archives/edgar/data/1133869/000110465926100071/capr-20260824xex99d1.htm; Capricor press release, 2026-09-17: https://www.capricor.com/investors/news-events/press-releases/detail/355/capricor-therapeutics-to-present-hope-3-and-hope-3; Stocktwits report carried by Yahoo Finance, 2026-09-30: https://finance.yahoo.com/markets/stocks/articles/why-did-capr-stock-jump-012424265.html; FDA Briefing Document, sections 2.1.3, 3.2.1.1 and 3.2.2: https://www.fda.gov/media/193839/download; FDA presentation, slide 57 and regulatory-history backup slide: https://www.fda.gov/media/193912/download"
    },
    {
      "factor": "Doubts about how the trial was run",
      "direction": "-",
      "step": "small",
      "evidence": "FDA's briefing says a preliminary review of audit trails found the sponsor departed from its approved blinding plan and moved statistics from an independent vendor to an in-house team in October 2023. It also notes that hypersensitivity reactions in 41.5% of deramiocel patients versus 15.4% on placebo could have revealed treatment assignment. An FDA inspection of the sponsor's clinical operations (6-20 July 2026) ended with a Form 483 with one observation; on 14 August 2026 Capricor said it had responded and was awaiting feedback. FDA's classification of that inspection is not public.",
      "source": "FDA Briefing Document, sections 1.3 and 3.2.4.2: https://www.fda.gov/media/193839/download; Capricor 8-K, 2026-07-29: https://www.sec.gov/Archives/edgar/data/1133869/000110465926087891/capr-20260729x8k.htm; Capricor 10-Q filed 2026-08-14: https://www.sec.gov/Archives/edgar/data/1133869/000110465926097294/capr-20260630x10q.htm"
    },
    {
      "factor": "Frequent hypersensitivity reactions and a heart-volume signal",
      "direction": "-",
      "step": "small",
      "evidence": "In HOPE-3, hypersensitivity reactions occurred in 22 of 53 patients (41.5%) on deramiocel and 8 of 52 (15.4%) on placebo. One placebo patient had a Grade 4 anaphylactic reaction that FDA says may have been caused by the product's excipients. Serious adverse events were fewer on deramiocel (1) than on placebo (5). FDA's analysis also shows the indexed left-ventricular end-diastolic volume rising more on deramiocel (difference 4.78, 95% CI 0.69 to 8.87; nominal p=0.02), and a few committee members reportedly wanted that examined as a possible safety signal. FDA's conclusion is that, given these risks, benefit-risk \"appears unfavorable in the absence of evidence of effectiveness\".",
      "source": "FDA Briefing Document, section 3.3, Table 11 and section 4: https://www.fda.gov/media/193839/download; FDA presentation, slide 21: https://www.fda.gov/media/193912/download; NeurologyLive, 2026-07-29: https://www.neurologylive.com/view/fda-advisory-committee-votes-against-deramiocel-dmd-cardiomyopathy"
    },
    {
      "factor": "No sign of labeling talks; the company has turned cautious",
      "direction": "-",
      "step": "small",
      "evidence": "In May 2026 Capricor expected labeling discussions to start soon. Its briefing document for the July meeting said they had not yet occurred, and nothing filed since mentions them. On 13 August 2026 it said commercial readiness was advancing more slowly until there is regulatory clarity, put programmes unrelated to deramiocel on hold, and took no questions on its results call, citing the sensitivity of its discussions with FDA. The 10-Q of 14 August says the committee vote is expected to weigh significantly on approvability for cardiomyopathy and that FDA may issue a complete response letter on the amended application. As of 4 October 2026 Capricor has filed no 8-K since 24 August 2026.",
      "source": "Capricor 8-K exhibit 99.1, 2026-05-12: https://www.sec.gov/Archives/edgar/data/1133869/000110465926059380/capr-20260512xex99d1.htm; Capricor 8-K exhibit 99.1, 2026-08-13: https://www.sec.gov/Archives/edgar/data/1133869/000110465926095908/capr-20260813xex99d1.htm; Capricor briefing document, section 1.3: https://www.fda.gov/media/193840/download; Capricor 10-Q filed 2026-08-14: https://www.sec.gov/Archives/edgar/data/1133869/000110465926097294/capr-20260630x10q.htm; Q2 2026 results call transcript, 2026-08-13: https://www.fool.com/earnings/call-transcripts/2026/08/20/capricor-capr-q2-2026-earnings-call-transcript/; SEC EDGAR filing list for Capricor (CIK 1133869)"
    },
    {
      "factor": "FDA extended the review instead of rejecting in August",
      "direction": "+",
      "step": "medium",
      "evidence": "FDA did not act on the 22 August 2026 goal date. Capricor's 10-Q of 14 August said FDA had indicated it was willing to review an amendment and, on receipt, to extend the action date; on 24 August the company said FDA had classified the amendment as a major amendment and moved the goal date to 22 November 2026. Capricor says CBER cited the significant unmet need in DMD; no FDA text is public. Under FDA's user-fee commitments, an extension should, \"except in rare circumstances\", be limited to cases where the new information could lead to approval in the current cycle. Capricor said on 13 August that it was working with FDA on a potential path focused on an upper-limb indication, and the patient group PPMD wrote on 21 August that the review had shifted toward upper-limb function in patients who already have upper-limb impairment. The signal has limits: FDA agreed to extend before the amendment was submitted, and its trial inspection was still unresolved. Only one extension is allowed per cycle, so there is no further formal extension, though FDA can act after a goal date; 22 November 2026 is a Sunday.",
      "source": "Capricor 10-Q filed 2026-08-14 (Next Steps): https://www.sec.gov/Archives/edgar/data/1133869/000110465926097294/capr-20260630x10q.htm; Capricor 8-K exhibit 99.1, 2026-08-24: https://www.sec.gov/Archives/edgar/data/1133869/000110465926100071/capr-20260824xex99d1.htm; PDUFA performance goals FY2023-2027, section I.A.5: https://www.fda.gov/media/151712/download; Q2 2026 results call transcript, 2026-08-13: https://www.fool.com/earnings/call-transcripts/2026/08/20/capricor-capr-q2-2026-earnings-call-transcript/; Parent Project Muscular Dystrophy, 2026-08-21: https://www.parentprojectmd.org/deramiocel-where-we-are-today/"
    },
    {
      "factor": "CBER has new leadership, and there are precedents for overruling reviewers",
      "direction": "+",
      "step": "medium",
      "evidence": "Karim Mikhail, acting CBER director from May 2026 and director since 9 September 2026, was also listed as acting head of the reviewing office at the July meeting, where he said the review team had not made a final decision. He has argued publicly for a regulatory framework adapted to rare diseases. In August 2026, according to BioSpace, a senior CBER official overruled a review team that wanted to reject Replimune's melanoma therapy again and it received accelerated approval; a 10-3 favourable committee vote weighed heavily in that decision. FDA has also accepted that existing data for uniQure's Huntington's gene therapy can support an application, reversing an earlier demand for a new trial. In DMD itself, FDA expanded Elevidys in June 2024 although its randomized trial \"failed to meet its statistical primary endpoint\" and, according to BioPharma Dive, three FDA review teams had recommended rejection. Against this: the negative July briefing was issued while Mikhail already held both posts, and no case was found of the current leadership approving against both its reviewers and a negative committee vote. The director in office at the 2025 rejection left in April 2026.",
      "source": "FDA meeting roster, 2026-07-29: https://www.fda.gov/media/193856/download; Bloomberg Law, 2026-08-10: https://news.bloomberglaw.com/health-law-and-business/rare-disease-drugmakers-watch-fda-for-renewed-focus-on-therapies; BioSpace, 2026-09-03: https://www.biospace.com/fda/replimunes-melanoma-drug-would-have-been-rejected-again-if-not-for-senior-cber-official; BioSpace, 2026-09-21: https://www.biospace.com/fda/mikhail-davis-on-board-with-regulatory-framework-tailored-to-rare-disease-therapies; BioPharm International, 2026-09-09: https://www.biopharminternational.com/view/hhs-names-karim-mikhail-as-cber-director-michael-davis-as-cder-director-in-broader-fda-leadership-shake-up; FDA press release, 2024-06-20: https://www.fda.gov/news-events/press-announcements/fda-expands-approval-gene-therapy-patients-duchenne-muscular-dystrophy; BioPharma Dive, 2024-06-21: https://www.biopharmadive.com/news/peter-marks-fda-sarepta-disagree-rift-elevidys-review/719480/"
    },
    {
      "factor": "FDA has recently approved drugs after negative committee votes",
      "direction": "+",
      "step": "small",
      "evidence": "In 2025 FDA approved Zusduri and Blenrep after negative committee votes, 2 of the 7 meetings held that year; counting 1 rejection after a positive vote, Jefferies found FDA went against its committee in 3 of 7 meetings (43%), against 16% in 2020-2024. In 2026 AstraZeneca's camizestrant received accelerated approval on 4 September, after a committee that did not reach a majority in its favour in April and a goal-date extension announced on 27 May to review additional analyses. The parallel is loose: FDA had requested camizestrant's extra analyses, whereas Capricor proposed its amendment, and in deramiocel's case FDA's own reviewers, not only the committee, dispute that the pivotal trial succeeded.",
      "source": "BioSpace citing Jefferies, 2026-01-06: https://www.biospace.com/fda/fda-went-against-adcomm-votes-more-held-fewer-adcomms-in-2025; AstraZeneca release, 2026-05-27: https://www.astrazeneca.com/media-centre/press-releases/2026/us-fda-decision-date-camizestrant-extended.html; FDA approval notice, 2026-09-04: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative"
    },
    {
      "factor": "Upper-limb results lean toward the drug, and the unmet need is high",
      "direction": "+",
      "step": "small",
      "evidence": "In FDA's own tables the overall upper-limb estimates favour deramiocel without reaching significance on the planned analysis: 0.66 points on the original plan; 0.92 (p=0.11) when the later handling of two placebo patients' data is applied; 0.69 on the mid-level PUL 2.0 score (95% CI 0.007 to 1.36; nominal p=0.048); and 1.75 (p=0.092) in the cohort given product from the commercial site, against -0.09 (p=0.90) in the first cohort. Capricor's absolute-change analysis gives 1.08 points (95% CI 0.00 to 2.16; p=0.0503). FDA treats a change of at least 1 point as clinically relevant. FDA \"recognizes the high unmet need for additional safe and effective therapies\" in DMD, and after the 2025 rejection it told Capricor (as quoted by the company) that it would \"exercise further regulatory flexibility\" by reviewing HOPE-3 with PUL as its primary endpoint. Deramiocel holds orphan, rare pediatric disease and RMAT designations. Against this, FDA's opening slides in July 2026 state that the same standard applies to common and rare diseases, and to traditional and accelerated approval.",
      "source": "FDA Briefing Document, Tables 3, 7, 8 and 11, sections 3.2.4.2 and 4: https://www.fda.gov/media/193839/download; Capricor briefing document, sections 1.3 and 6.4: https://www.fda.gov/media/193840/download; FDA introductory slides, slide 11: https://www.fda.gov/media/193913/download"
    },
    {
      "factor": "Manufacturing does not look like the obstacle",
      "direction": "+",
      "step": "small",
      "evidence": "The San Diego plant had its pre-license inspection on 27-30 May 2025, which ended with 5 observations, and Capricor's annual report says FDA accepted all its responses. FDA's July 2026 briefing says its manufacturing reviewers consider product from the earlier Los Angeles facility and from San Diego \"to be equivalent\", and no manufacturing question was put to the committee. The usual manufacturing risk for a first product therefore looks lower here. The manufacturing and facility sections of the 2025 complete response letter are redacted; Capricor says they held 6 deficiencies and that all were resolved.",
      "source": "FDA Form 483, Capricor, Inc., 2025-05-30: https://www.fda.gov/media/188877/download; Capricor 10-K filed 2026-03-17: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm; FDA Briefing Document, notes to Figure 7 and Tables 7 and 8: https://www.fda.gov/media/193839/download; Capricor briefing document, section 4.1: https://www.fda.gov/media/193840/download; FDA Complete Response Letter, 2025-07-09: https://download.open.fda.gov/crl/CRL_BLA125842_20250709.pdf"
    }
  ],
  "manufacturing_risk": {
    "level": "low",
    "why": "The commercial plant in San Diego was inspected by FDA on 27-30 May 2025. The 5 observations were: qualification studies that did not reflect actual manufacturing conditions, written procedures not followed, missing quality agreements with outside parties, missing written quality-control procedures for complaints and returns, and equipment in the manufacturing suite not kept in good repair. Capricor says FDA accepted all its responses. FDA's July 2026 briefing says its manufacturing reviewers consider product from the two sites equivalent, and on 12 May 2026 Capricor said it had been able to address all FDA information requests received up to then. What cannot be judged: the 2025 complete response letter contained manufacturing and facility sections (6 deficiencies, per Capricor) that are redacted, and their resolution is stated only by the company. This is also a cell therapy made from donor hearts and the company's first commercial product."
  },
  "what_would_change_my_mind": [
    "Up: Capricor discloses labeling negotiations, an FDA request for a post-marketing or confirmatory study, or any FDA proposal for a conditional route to an upper-limb label.",
    "Up: CBER leadership says publicly that the 24-month data or a totality-of-evidence reading supports the upper-limb indication, or approves another therapy against both its reviewers and a negative committee vote.",
    "Down: FDA classifies the July 2026 inspection of the HOPE-3 trial as requiring official action, or otherwise questions the reliability of the trial data.",
    "Down: Capricor announces a new randomized trial, cuts launch preparation further, or says FDA has asked for additional controlled data.",
    "Void rather than no: Capricor withdraws the application before FDA acts."
  ],
  "summary_en": "FDA approval of deramiocel in this review cycle is put at 20%, far below the 76% base rate for first-time applications from smaller companies. FDA's reviewers found that the pivotal HOPE-3 trial missed its planned primary endpoint (p=0.24) and that the evidence falls short for both heart and upper-limb function; an advisory committee voted 3-9 against on the heart indication and did not vote on upper limb. The company's positive result depends on an analysis plan rewritten after the trial ended. Approval remains possible because the decision now rests on discretion: FDA extended the review to 22 November 2026 instead of rejecting in August, and CBER has new leadership. Manufacturing does not appear to be the obstacle.",
  "summary_zh": "FDA 在本轮审评中批准 deramiocel 的概率估计为 20%，远低于小公司首次申请 76% 的基准。FDA 审评团队认定，关键试验 HOPE-3 按原定方案未达主要终点（p=0.24），心脏和上肢功能两方面的证据都不够；咨询委员会就心脏适应症以 3 比 9 投了反对票，上肢功能没有付诸表决。公司所说的阳性结果，靠的是试验结束后才改写的统计方案。之所以还有机会，是因为最终要看裁量：FDA 8 月没有直接拒绝，而是把 PDUFA 目标日期延到 2026 年 11 月 22 日，CBER 也换了领导层。生产环节看来不是障碍。",
  "sources": [
    "FDA Briefing Document, BLA 125842, Cellular, Tissue and Gene Therapies Advisory Committee, 2026-07-29: https://www.fda.gov/media/193839/download",
    "FDA presentation slides, BLA 125842, 2026-07-29: https://www.fda.gov/media/193912/download",
    "FDA introductory slides and discussion topics, 2026-07-29: https://www.fda.gov/media/193913/download",
    "FDA voting question, 2026-07-29: https://www.fda.gov/media/193857/download",
    "FDA meeting roster, 2026-07-29: https://www.fda.gov/media/193856/download",
    "Capricor briefing document for the 2026-07-29 advisory committee: https://www.fda.gov/media/193840/download",
    "FDA Complete Response Letter, BL 125842/0, 2025-07-09: https://download.open.fda.gov/crl/CRL_BLA125842_20250709.pdf",
    "FDA Form 483, Capricor, Inc., San Diego, 2025-05-30: https://www.fda.gov/media/188877/download",
    "PDUFA Reauthorization Performance Goals and Procedures FY2023-2027: https://www.fda.gov/media/151712/download",
    "Capricor 8-K exhibit 99.1, 2026-08-24: https://www.sec.gov/Archives/edgar/data/1133869/000110465926100071/capr-20260824xex99d1.htm",
    "Capricor 10-Q for Q2 2026, filed 2026-08-14: https://www.sec.gov/Archives/edgar/data/1133869/000110465926097294/capr-20260630x10q.htm",
    "Capricor 8-K exhibit 99.1, 2026-08-13: https://www.sec.gov/Archives/edgar/data/1133869/000110465926095908/capr-20260813xex99d1.htm",
    "Capricor Q2 2026 results call transcript, 2026-08-13: https://www.fool.com/earnings/call-transcripts/2026/08/20/capricor-capr-q2-2026-earnings-call-transcript/",
    "Capricor 8-K, 2026-07-30: https://www.sec.gov/Archives/edgar/data/1133869/000110465926088667/capr-20260729x8k.htm",
    "Capricor 8-K, 2026-07-29: https://www.sec.gov/Archives/edgar/data/1133869/000110465926087891/capr-20260729x8k.htm",
    "Capricor 8-K exhibit 99.1, 2026-05-12: https://www.sec.gov/Archives/edgar/data/1133869/000110465926059380/capr-20260512xex99d1.htm",
    "Capricor 10-K for FY2025, filed 2026-03-17: https://www.sec.gov/Archives/edgar/data/1133869/000110465926029580/capr-20251231x10k.htm",
    "Capricor press release, 2026-09-17: https://www.capricor.com/investors/news-events/press-releases/detail/355/capricor-therapeutics-to-present-hope-3-and-hope-3",
    "SEC EDGAR filing list for Capricor Therapeutics (CIK 1133869), as of 2026-10-04",
    "Stocktwits report carried by Yahoo Finance, 2026-09-30 (24-month open-label data from the World Muscle Society poster): https://finance.yahoo.com/markets/stocks/articles/why-did-capr-stock-jump-012424265.html",
    "Parent Project Muscular Dystrophy, 2026-08-21: https://www.parentprojectmd.org/deramiocel-where-we-are-today/",
    "BioSpace, 2026-07-29: https://www.biospace.com/fda/fda-advisers-vote-against-approval-of-capricors-dmd-therapy-in-chaotic-adcomm-meeting",
    "NeurologyLive, 2026-07-29: https://www.neurologylive.com/view/fda-advisory-committee-votes-against-deramiocel-dmd-cardiomyopathy",
    "BioPharma Dive, 2026-07-29: https://www.biopharmadive.com/news/capricor-fda-vote-deramiocel-duchenne-cardiomyopathy/826465/",
    "Bloomberg Law, 2026-08-10: https://news.bloomberglaw.com/health-law-and-business/rare-disease-drugmakers-watch-fda-for-renewed-focus-on-therapies",
    "BioSpace, 2026-09-03: https://www.biospace.com/fda/replimunes-melanoma-drug-would-have-been-rejected-again-if-not-for-senior-cber-official",
    "BioSpace, 2026-09-21: https://www.biospace.com/fda/mikhail-davis-on-board-with-regulatory-framework-tailored-to-rare-disease-therapies",
    "BioPharm International, 2026-09-09: https://www.biopharminternational.com/view/hhs-names-karim-mikhail-as-cber-director-michael-davis-as-cder-director-in-broader-fda-leadership-shake-up",
    "FDA press release on Elevidys, 2024-06-20: https://www.fda.gov/news-events/press-announcements/fda-expands-approval-gene-therapy-patients-duchenne-muscular-dystrophy",
    "BioPharma Dive, 2024-06-21: https://www.biopharmadive.com/news/peter-marks-fda-sarepta-disagree-rift-elevidys-review/719480/",
    "FDA approval notice for camizestrant, 2026-09-04: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative",
    "AstraZeneca release, 2026-05-27: https://www.astrazeneca.com/media-centre/press-releases/2026/us-fda-decision-date-camizestrant-extended.html",
    "BioSpace citing Jefferies, 2026-01-06: https://www.biospace.com/fda/fda-went-against-adcomm-votes-more-held-fewer-adcomms-in-2025"
  ],
  "zh": {
    "indication": "杜氏肌营养不良（DMD）；修订后的拟定适应症聚焦上肢功能，最初申报的是 DMD 心肌病",
    "key_factors": [
      {
        "factor": "FDA 审评团队认为关键试验失败，上肢和心脏两方面都是如此",
        "evidence": "在为 2026 年 7 月 29 日咨询委员会准备的简报文件中，FDA 按最初的统计分析方案分析了 HOPE-3：主要终点（PUL 2.0 总分）组间差为 0.66 分（95% CI -0.45 至 1.77；p=0.24），而试验的把握度是按检出 1.5 分的差异设计的；关键次要终点（LVEF）组间差为 -0.041 个百分点（p=0.97）。审评团队的结论是：这些数据不能为 deramiocel 在 DMD 中的有效性提供实质性证据，也找不出可能获益的亚组人群，获益风险评估偏向不利。这一结论同样涵盖上肢功能，也就是目前在审的适应症。"
      },
      {
        "factor": "公司的阳性结果依赖试验结束后改写的统计分析方案",
        "evidence": "Capricor 报告主要终点达到统计学显著（4.55 个百分点，p=0.029；2026 年 7 月发表于 The Lancet）。FDA 指出，该结果所依据的 3.0 版方案定稿于 2025 年 11 月 24 日，距盲态阶段于 2025 年 6 月 18 日结束已过去五个多月，又恰在 2025 年 11 月 25 日数据揭盲的前一天，申报前并未提交 FDA 审阅；FDA 把由此得出的分析一律视为事后的探索性分析。按 FDA 的复核，严格照 3.0 版方案计算，差值为 4.16%（p=0.045）；两名安慰剂组患者的数据改按原定方式处理后，降至 2.53%（p=0.21）。2.0 版是最后一个提交给 FDA 的方案（2025 年 9 月 26 日），得到的是 3.74%（p=0.08）或 2.38%（p=0.26）。2026 年 7 月 29 日，Capricor 自行把 LVEF 结果更正为 p=0.09（组间差 1.8 个百分点），此前公布的是 p=0.04（2.4 个百分点）。"
      },
      {
        "factor": "因疗效问题收到完全回应函（CRL）后的第二轮审评，且没有独立的佐证",
        "evidence": "FDA 在 2025 年 7 月 9 日的完全回应函（CRL）中写明，该申请未达到实质性有效性证据的法定要求。函中建议开展以心脏结局为主要目的的对照研究，前提是 Capricor 寻求心肌病适应症；对于笼统的 DMD 适应症，FDA 早在 2024 年 8 月就建议申请应包含 HOPE-3 的结果，2025 年 8 月又没有同意 Capricor 把 HOPE-3 的主要终点改为 LVEF。因此，就上肢功能而言 HOPE-3 是对口的试验，但它孤立无援：更早的 HOPE-2 试验（20 名患者，提前终止）未达主要终点（2.98 分，p=0.13），FDA 还写明，所提出的作用机制不够特异，作为疾病修饰疗法在生物学上并不可信。首次重新提交（2025 年 12 月 29 日）于 2026 年 1 月 13 日被认定为材料不全。76% 的基准描述的是首次申请。"
      },
      {
        "factor": "咨询委员会就心脏适应症以 3 比 9 投了反对票，上肢功能没有付诸表决",
        "evidence": "2026 年 7 月 29 日，FDA 细胞、组织与基因治疗咨询委员会就现有证据能否构成 deramiocel 治疗 DMD 心肌病有效性的实质性证据进行表决，结果为 3 票赞成、9 票反对、0 票弃权。上肢功能只列为讨论议题、没有表决，因此目前在审的适应症并未得到委员会背书。据媒体报道，投反对票的委员提到结果对缺失数据的处理方式很敏感，主要是 LVEF，上肢终点的程度轻一些；一位统计学家称结果非常脆弱，另一位认为上肢数据略好一些，但表示仍未被说服该产品有效。投赞成票的委员则看重上肢数据。Capricor 称上肢功能的讨论在方向上是支持的，这只是公司自己的说法。"
      },
      {
        "factor": "补充材料只增加了无对照数据",
        "evidence": "8 月提交的补充材料新增了 24 个月开放标签扩展数据和进一步分析，没有新的随机对照比较。FDA 曾在 2026 年 5 月 14 日要求提供长期临床数据。Capricor 称，106 名随机入组患者中有 82 名到达第 24 个月（原 deramiocel 组 40 名，原安慰剂组 42 名）；完成盲态一年的有 101 名。据 2026 年 9 月 30 日对 World Muscle Society 年会壁报的报道：由安慰剂转为用药的患者，PUL 评分在盲态的一年里下降 2.05 分，在开放标签的一年里下降 0.49 分；全程使用 deramiocel 的患者先后下降 0.95 分和 0.89 分。FDA 曾写明，PUL 评分在开放标签条件下可能受偏倚影响，并在会上告诉委员会，此前那项开放标签研究的事后分析不能提供实质性有效性证据。"
      },
      {
        "factor": "试验的执行方式受到质疑",
        "evidence": "FDA 简报文件称，对稽查轨迹的初步审查发现，申办方偏离了经批准的设盲计划，并在 2023 年 10 月把统计工作从独立供应商转到公司内部团队。文件还指出，deramiocel 组 41.5% 的患者出现超敏反应，安慰剂组为 15.4%，这一差别可能让人推断出分组情况。FDA 对申办方临床运营的检查（2026 年 7 月 6 日至 20 日）结束时开出一份含一项观察项的 Form 483；Capricor 在 2026 年 8 月 14 日表示已提交答复，正在等待反馈。FDA 对这次检查的定性尚未公开。"
      },
      {
        "factor": "超敏反应多见，并出现心室容积信号",
        "evidence": "在 HOPE-3 中，deramiocel 组 53 名患者中有 22 名（41.5%）出现超敏反应，安慰剂组 52 名中有 8 名（15.4%）。一名安慰剂组患者发生 4 级过敏性反应，FDA 认为可能与产品辅料有关。严重不良事件 deramiocel 组为 1 例，少于安慰剂组的 5 例。FDA 的分析还显示，deramiocel 组左心室舒张末期容积指数上升更多（组间差 4.78，95% CI 0.69 至 8.87；名义 p=0.02），据报道有几位委员希望把它当作潜在安全信号进一步评估。FDA 的结论是：考虑到这些风险，在缺乏有效性证据的情况下，获益风险评估偏向不利。"
      },
      {
        "factor": "未见标签讨论的迹象，公司态度转为谨慎",
        "evidence": "2026 年 5 月，Capricor 曾预计标签讨论很快开始；它为 7 月会议准备的简报文件仍写明讨论尚未进行，此后的披露文件也再没有提到。2026 年 8 月 13 日，公司表示在监管结果明朗之前放慢商业化准备，暂停了与 deramiocel 无关的项目，并以与 FDA 的沟通敏感为由，在业绩电话会上不设问答环节。8 月 14 日的 10-Q 写明，委员会的表决预计会显著影响心肌病适应症的可批准性，FDA 也可能就修订后的申请发出完全回应函（CRL）。截至 2026 年 10 月 4 日，Capricor 自 2026 年 8 月 24 日以来没有再提交 8-K。"
      },
      {
        "factor": "FDA 在 8 月选择延长审评而不是直接拒绝",
        "evidence": "FDA 没有在 2026 年 8 月 22 日的目标日期作出决定。Capricor 8 月 14 日的 10-Q 称，FDA 已表示愿意审阅补充材料，并在收到后相应延后目标日期；8 月 24 日公司宣布，FDA 把该材料认定为重大补充，PDUFA 目标日期推到 2026 年 11 月 22 日。Capricor 称 CBER 提到 DMD 存在重大未满足需求，但 FDA 方面没有公开文字。按 FDA 的处方药使用者付费承诺，除极少数情况外，延期应仅限于新资料有可能促成本轮获批的情形。Capricor 在 8 月 13 日表示，正与 FDA 探讨以上肢功能适应症为重点的可能路径；患者组织 PPMD 在 8 月 21 日写道，审评重点已转向已有上肢功能受损患者的上肢功能。这一信号也有局限：FDA 在补充材料提交之前就同意延期，当时它对试验的检查也还没有结论。每个审评周期只能延期一次，因此不会再有正式延期，但 FDA 可以晚于目标日期作出决定；2026 年 11 月 22 日是星期日。"
      },
      {
        "factor": "CBER 换了领导层，且有推翻审评团队意见的先例",
        "evidence": "Karim Mikhail 自 2026 年 5 月起任 CBER 代理主任，2026 年 9 月 9 日起正式出任主任；在 7 月会议的名单上，他同时是负责本申请的审评办公室的代理主任，并在会上表示审评团队尚未作出最终决定。他公开主张为罕见病建立相适应的监管框架。据 BioSpace 报道，2026 年 8 月，CBER 一位高层官员否决了审评团队再次拒绝 Replimune 黑色素瘤疗法的意见，该疗法获得加速批准；咨询委员会 10 比 3 的赞成票在这一决定中分量很重。FDA 还认可 uniQure 亨廷顿病基因疗法的现有数据足以支持提交申请，改变了此前要求另做试验的立场。在 DMD 领域，FDA 于 2024 年 6 月扩大了 Elevidys 的适用范围，尽管其随机试验未达统计学主要终点，而且据 BioPharma Dive 报道，FDA 有三个审评团队建议拒绝。反面的事实是：7 月那份否定性的简报文件发布时，Mikhail 已身兼上述两职；也没有找到现任领导层在审评团队和咨询委员会都反对的情况下仍予批准的先例。2025 年作出拒绝决定时在任的主任已于 2026 年 4 月离任。"
      },
      {
        "factor": "FDA 近期有在咨询委员会反对后仍予批准的例子",
        "evidence": "2025 年，FDA 在委员会投反对票后仍批准了 Zusduri 和 Blenrep，占当年 7 次会议中的 2 次；再算上 1 次赞成票后仍未获批的情形，据 Jefferies 统计，当年 7 次会议中有 3 次（43%）FDA 的决定与委员会意见相反，而 2020-2024 年为 16%。2026 年，AstraZeneca 的 camizestrant 于 9 月 4 日获得加速批准，此前 4 月咨询委员会未形成多数支持，5 月 27 日公司宣布目标日期延后以审阅补充分析。两者只是形似：camizestrant 的补充分析是 FDA 主动要求的，而 Capricor 的补充材料出自公司提议；况且质疑 deramiocel 关键试验成功的不只是委员会，还有 FDA 自己的审评团队。"
      },
      {
        "factor": "上肢结果偏向药物一侧，未满足需求突出",
        "evidence": "在 FDA 自己的表格里，上肢功能的总体估计值偏向 deramiocel，但按原定分析都未达显著：原定方案下为 0.66 分；对两名安慰剂组患者的数据采用后来的处理方式时为 0.92 分（p=0.11）；PUL 2.0 中段评分为 0.69 分（95% CI 0.007 至 1.36；名义 p=0.048）；使用商业化场地产品的队列为 1.75 分（p=0.092），第一个队列为 -0.09 分（p=0.90）。Capricor 按绝对变化所做的分析为 1.08 分（95% CI 0.00 至 2.16；p=0.0503）。FDA 认为至少 1 分的变化才具有临床意义。FDA 承认 DMD 对更多安全有效疗法的需求远未满足；2025 年收到 CRL 之后，FDA 告诉 Capricor（据公司引述），将进一步行使监管灵活性，以 PUL 作为主要终点来审阅 HOPE-3。deramiocel 拥有孤儿药、罕见儿科疾病和 RMAT 资格。另一方面，FDA 在 2026 年 7 月会议的开场幻灯片中写明，常见病和罕见病适用同一标准，常规批准和加速批准也适用同一标准。"
      },
      {
        "factor": "生产环节看来不是障碍",
        "evidence": "圣迭戈工厂于 2025 年 5 月 27 日至 30 日接受许可前检查，结束时有 5 项观察项；Capricor 的年报称 FDA 已接受其全部答复。FDA 2026 年 7 月的简报文件写明，其生产审评人员认为早先的洛杉矶场地与圣迭戈场地生产的产品等同，会上也没有向委员会提出生产方面的问题。因此，首个产品常见的生产风险在这里相对较低。2025 年完全回应函（CRL）中的生产和设施章节已被涂黑；Capricor 称其中有 6 项缺陷，且均已解决。"
      }
    ],
    "manufacturing_risk_why": "圣迭戈的商业化工厂已于 2025 年 5 月 27 日至 30 日接受 FDA 检查。5 项观察项分别是：确认研究未能反映实际生产条件、书面规程未得到执行、未与外部机构签订质量协议、缺少处理投诉和退货的书面质量控制规程、生产车间内的设备维护不善。Capricor 称 FDA 已接受其全部答复。FDA 2026 年 7 月的简报文件写明，其生产审评人员认为两处场地的产品等同；Capricor 在 2026 年 5 月 12 日表示，截至当时收到的 FDA 信息要求均已答复。无法判断的部分：2025 年的完全回应函（CRL）含有生产和设施章节（按 Capricor 的说法有 6 项缺陷），内容已被涂黑，是否解决只有公司单方面的说法。此外，这是一种取自捐献者心脏的细胞疗法，也是该公司的第一个商业化产品。",
    "what_would_change_my_mind": [
      "上调：Capricor 披露已与 FDA 进行标签谈判、FDA 要求开展上市后或确证性研究，或 FDA 提出以附条件方式批准上肢功能适应症。",
      "上调：CBER 领导层公开表示 24 个月数据或综合证据足以支持上肢功能适应症，或又批准一款同时遭审评团队和咨询委员会反对的疗法。",
      "下调：FDA 把 2026 年 7 月针对 HOPE-3 试验的检查定性为需采取官方行动，或以其他方式质疑试验数据的可靠性。",
      "下调：Capricor 宣布开展新的随机对照试验、进一步收缩上市准备，或表示 FDA 要求补充对照数据。",
      "作废而非判否：Capricor 在 FDA 作出决定前撤回申请。"
    ]
  },
  "recorded_at": "2026-10-05T00:33:07+00:00"
}